Adverum Biotechnologies (NASDAQ:ADVM) vs. Pluri (NASDAQ:PLUR) Head to Head Review

Adverum Biotechnologies (NASDAQ:ADVM) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, analyst recommendations and risk.

Profitability

This table compares Adverum Biotechnologies and Pluri’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adverum Biotechnologies	N/A	-65.14%	-40.52%
Pluri	-4,184.28%	-917.18%	-82.85%

Valuation and Earnings

This table compares Adverum Biotechnologies and Pluri”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adverum Biotechnologies	$3.60 million	25.83	-$117.17 million	($5.99)	-0.75
Pluri	$330,000.00	71.77	-$20.89 million	($6.03)	-0.71

Pluri has lower revenue, but higher earnings than Adverum Biotechnologies. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

48.2% of Adverum Biotechnologies shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 4.2% of Adverum Biotechnologies shares are held by company insiders. Comparatively, 10.2% of Pluri shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Adverum Biotechnologies has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, Pluri has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Adverum Biotechnologies and Pluri, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adverum Biotechnologies	0	1	5	0	2.83
Pluri	0	0	0	0	0.00

Adverum Biotechnologies presently has a consensus target price of $27.83, indicating a potential upside of 522.67%. Given Adverum Biotechnologies’ stronger consensus rating and higher probable upside, analysts plainly believe Adverum Biotechnologies is more favorable than Pluri.

Summary

Adverum Biotechnologies beats Pluri on 9 of the 14 factors compared between the two stocks.

About Adverum Biotechnologies

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

About Pluri

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.